scispace - formally typeset
Open AccessJournal ArticleDOI

ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients.

Reads0
Chats0
TLDR
This part of the EFISG guidelines focuses on non-neutropenic adult patients, and liposomal amphotericin B and voriconazole are supported with moderate, and fluconazole with marginal strength for the targeted initial treatment of candidaemia.
About
This article is published in Clinical Microbiology and Infection.The article was published on 2012-12-01 and is currently open access. It has received 1011 citations till now. The article focuses on the topics: Amphotericin B deoxycholate & Flucytosine.

read more

Citations
More filters
Journal ArticleDOI

Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016

Andrew Rhodes, +58 more
TL;DR: Although a significant number of aspects of care have relatively weak support, evidence-based recommendations regarding the acute management of sepsis and septic shock are the foundation of improved outcomes for these critically ill patients with high mortality.
Journal ArticleDOI

Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016.

Andrew Rhodes, +58 more
TL;DR: A consensus committee of 55 international experts representing 25 international organizations was assembled at key international meetings (forSurviving Sepsis Campaign Guidelines for Management of Sepsis and Septic Shock: 2012 as discussed by the authors ).
Journal ArticleDOI

Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline

Andrew J. Ullmann, +58 more
TL;DR: Treatment duration for aspergillosis is strongly recommended based on clinical improvement, degree of immunosuppression and response on imaging, and in refractory disease, where a personalized approach considering reversal of predisposing factors, switching drug class and surgical intervention is also strongly recommended.
Journal ArticleDOI

Candida albicans Biofilms and Human Disease.

TL;DR: Current knowledge of biofilms formed by C. albicans and closely related fungal species are reviewed, finding that these biofilm-based infections are intrinsically resistant to conventional antifungal therapeutics, the host immune system, and other environmental perturbations.
Journal ArticleDOI

ESCMID† and ECMM‡ joint clinical guidelines for the diagnosis and management of mucormycosis 2013

TL;DR: These European Society for Clinical Microbiology and Infectious Diseases and European Confederation of Medical Mycology Joint Clinical Guidelines focus on the diagnosis and management of mucormycosis and strongly recommend continuing treatment until complete response demonstrated on imaging and permanent reversal of predisposing factors.
References
More filters
Journal ArticleDOI

Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group

TL;DR: These revised definitions of invasive fungal disease are intended to advance clinical and epidemiological research and may serve as a useful model for defining other infections in high-risk patients.
Journal ArticleDOI

Microbial Biofilms: from Ecology to Molecular Genetics

TL;DR: The recent explosion in the field of biofilm research has led to exciting progress in the development of new technologies for studying these communities, advanced the authors' understanding of the ecological significance of surface-attached bacteria, and provided new insights into the molecular genetic basis ofBiofilm development.
Journal ArticleDOI

Comparison of caspofungin and amphotericin B for invasive candidiasis.

TL;DR: Caspofungin is at least as effective as amphotericin B for the treatment of invasive candidiasis and, more specifically, candidemia.
Related Papers (5)